Characterization	0	16	O
of	17	19	O
the	20	23	O
metabolic	24	33	O
changes	34	41	O
underlying	42	52	O
growth	53	59	O
factor	60	66	O
angiogenic	67	77	O
activation	78	88	O
:	88	89	O
identification	90	104	O
of	105	107	O
new	108	111	O
potential	112	121	O
therapeutic	122	133	O
targets	134	141	O
.	141	142	O

Angiogenesis	144	156	O
is	157	159	O
a	160	161	O
fundamental	162	173	O
process	174	181	O
to	182	184	O
normal	185	191	O
and	192	195	O
abnormal	196	204	O
tissue	205	211	B-Tissue
growth	212	218	O
and	219	222	O
repair	223	229	O
,	229	230	O
which	231	236	O
consists	237	245	O
of	246	248	O
recruiting	249	259	O
endothelial	260	271	B-Cell
cells	272	277	I-Cell
toward	278	284	O
an	285	287	O
angiogenic	288	298	O
stimulus	299	307	O
.	307	308	O

The	309	312	O
cells	313	318	B-Cell
subsequently	319	331	O
proliferate	332	343	O
and	344	347	O
differentiate	348	361	O
to	362	364	O
form	365	369	O
endothelial	370	381	B-Tissue
tubes	382	387	I-Tissue
and	388	391	O
capillary	392	401	B-Tissue
-	401	402	I-Tissue
like	402	406	I-Tissue
structures	407	417	I-Tissue
.	417	418	O

Little	419	425	O
is	426	428	O
known	429	434	O
about	435	440	O
the	441	444	O
metabolic	445	454	O
adaptation	455	465	O
of	466	468	O
endothelial	469	480	B-Cell
cells	481	486	I-Cell
through	487	494	O
such	495	499	O
a	500	501	O
transformation	502	516	O
.	516	517	O

We	518	520	O
studied	521	528	O
the	529	532	O
metabolic	533	542	O
changes	543	550	O
of	551	553	O
endothelial	554	565	B-Cell
cell	566	570	I-Cell
activation	571	581	O
by	582	584	O
growth	585	591	O
factors	592	599	O
using	600	605	O
human	606	611	B-Cell
umbilical	612	621	I-Cell
vein	622	626	I-Cell
endothelial	627	638	I-Cell
cells	639	644	I-Cell
(	645	646	O
HUVECs	646	652	B-Cell
)	652	653	O
,	653	654	O
[	655	656	B-Drug_or_compound
1	656	657	I-Drug_or_compound
,	657	658	I-Drug_or_compound
2	658	659	I-Drug_or_compound
-	659	660	I-Drug_or_compound
(	660	661	I-Drug_or_compound
13	661	663	I-Drug_or_compound
)	663	664	I-Drug_or_compound
C	664	665	I-Drug_or_compound
(	665	666	I-Drug_or_compound
2	666	667	I-Drug_or_compound
)	667	668	I-Drug_or_compound
]	668	669	I-Drug_or_compound
-	669	670	I-Drug_or_compound
glucose	670	677	I-Drug_or_compound
and	678	681	O
mass	682	686	O
isotopomer	687	697	O
distribution	698	710	O
analysis	711	719	O
.	719	720	O

The	721	724	O
metabolism	725	735	O
of	736	738	O
[	739	740	B-Drug_or_compound
1	740	741	I-Drug_or_compound
,	741	742	I-Drug_or_compound
2	742	743	I-Drug_or_compound
-	743	744	I-Drug_or_compound
(	744	745	I-Drug_or_compound
13	745	747	I-Drug_or_compound
)	747	748	I-Drug_or_compound
C	748	749	I-Drug_or_compound
(	749	750	I-Drug_or_compound
2	750	751	I-Drug_or_compound
)	751	752	I-Drug_or_compound
]	752	753	I-Drug_or_compound
-	753	754	I-Drug_or_compound
glucose	754	761	I-Drug_or_compound
by	762	764	O
HUVEC	765	770	B-Cell
allows	771	777	O
us	778	780	O
to	781	783	O
trace	784	789	O
many	790	794	O
of	795	797	O
the	798	801	O
main	802	806	O
glucose	807	814	B-Drug_or_compound
metabolic	815	824	O
pathways	825	833	O
,	833	834	O
including	835	844	O
glycogen	845	853	B-Drug_or_compound
synthesis	854	863	O
,	863	864	O
the	865	868	O
pentose	869	876	B-Drug_or_compound
cycle	877	882	O
and	883	886	O
the	887	890	O
glycolytic	891	901	O
pathways	902	910	O
.	910	911	O

So	912	914	O
we	915	917	O
established	918	929	O
that	930	934	O
these	935	940	O
pathways	941	949	O
were	950	954	O
crucial	955	962	O
to	963	965	O
endothelial	966	977	B-Cell
cell	978	982	I-Cell
proliferation	983	996	O
under	997	1002	O
vascular	1003	1011	B-Gene_or_gene_product
endothelial	1012	1023	I-Gene_or_gene_product
growth	1024	1030	I-Gene_or_gene_product
factor	1031	1037	I-Gene_or_gene_product
(	1038	1039	O
VEGF	1039	1043	B-Gene_or_gene_product
)	1043	1044	O
and	1045	1048	O
fibroblast	1049	1059	B-Gene_or_gene_product
growth	1060	1066	I-Gene_or_gene_product
factor	1067	1073	I-Gene_or_gene_product
(	1074	1075	O
FGF	1075	1078	B-Gene_or_gene_product
)	1078	1079	O
stimulation	1080	1091	O
.	1091	1092	O

A	1093	1094	O
specific	1095	1103	O
VEGF	1104	1108	B-Gene_or_gene_product
receptor	1109	1117	I-Gene_or_gene_product
-	1117	1118	I-Gene_or_gene_product
2	1118	1119	I-Gene_or_gene_product
inhibitor	1120	1129	O
demonstrated	1130	1142	O
the	1143	1146	O
importance	1147	1157	O
of	1158	1160	O
glycogen	1161	1169	B-Drug_or_compound
metabolism	1170	1180	O
and	1181	1184	O
pentose	1185	1192	B-Drug_or_compound
cycle	1193	1198	O
pathway	1199	1206	O
.	1206	1207	O

Furthermore	1208	1219	O
,	1219	1220	O
we	1221	1223	O
showed	1224	1230	O
that	1231	1235	O
glycogen	1236	1244	B-Drug_or_compound
was	1245	1248	O
depleted	1249	1257	O
in	1258	1260	O
a	1261	1262	O
low	1263	1266	O
glucose	1267	1274	B-Drug_or_compound
medium	1275	1281	O
,	1281	1282	O
but	1283	1286	O
conserved	1287	1296	O
under	1297	1302	O
hypoxic	1303	1310	O
conditions	1311	1321	O
.	1321	1322	O

Finally	1323	1330	O
,	1330	1331	O
we	1332	1334	O
demonstrated	1335	1347	O
that	1348	1352	O
direct	1353	1359	O
inhibition	1360	1370	O
of	1371	1373	O
key	1374	1377	O
enzymes	1378	1385	O
to	1386	1388	O
glycogen	1389	1397	B-Drug_or_compound
metabolism	1398	1408	O
and	1409	1412	O
pentose	1413	1420	B-Drug_or_compound
phosphate	1421	1430	O
pathways	1431	1439	O
reduced	1440	1447	O
HUVEC	1448	1453	B-Cell
viability	1454	1463	O
and	1464	1467	O
migration	1468	1477	O
.	1477	1478	O

In	1479	1481	O
this	1482	1486	O
regard	1487	1493	O
,	1493	1494	O
inhibitors	1495	1505	O
of	1506	1508	O
these	1509	1514	O
pathways	1515	1523	O
have	1524	1528	O
been	1529	1533	O
shown	1534	1539	O
to	1540	1542	O
be	1543	1545	O
effective	1546	1555	O
antitumoral	1556	1567	O
agents	1568	1574	O
.	1574	1575	O

To	1576	1578	O
sum	1579	1582	O
up	1583	1585	O
,	1585	1586	O
our	1587	1590	O
data	1591	1595	O
suggest	1596	1603	O
that	1604	1608	O
the	1609	1612	O
inhibition	1613	1623	O
of	1624	1626	O
metabolic	1627	1636	O
pathways	1637	1645	O
offers	1646	1652	O
a	1653	1654	O
novel	1655	1660	O
and	1661	1664	O
powerful	1665	1673	O
therapeutic	1674	1685	O
approach	1686	1694	O
,	1694	1695	O
which	1696	1701	O
simultaneously	1702	1716	O
inhibits	1717	1725	O
tumor	1726	1731	B-Cell
cell	1732	1736	I-Cell
proliferation	1737	1750	O
and	1751	1754	O
tumor	1755	1760	B-Pathological_formation
-	1760	1761	O
induced	1761	1768	O
angiogenesis	1769	1781	O
.	1781	1782	O

